Trial NCT 05175625; IRCT20150303021315N26
Publication Tabarsi P, Immunology, 2022
Primary outcome on the report: Seroconversion rate of neutralizing antibodies via surrogate virus-neutralizing test (sVNTw) on Day 14

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.